从ADC药物发展看乳腺癌精准靶向治疗未来  

Advances on Antibody-drug Conjugates Drug Development for Precise Targeted Therapy of Breast Cancer

作　　者：雷蕾 王晓稼 LEI lei;WANG Xiao-jia(The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Basic Medicine and Cancer(IBMC),Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]中国科学院大学附属肿瘤医院(浙江省肿瘤医院),中国科学院基础医学与肿瘤研究所,浙江杭州310022

出　　处：《肿瘤学杂志》2021年第7期515-520,共6页Journal of Chinese Oncology

摘　　要：抗体药物偶联物(antibody-drug conjugates,ADC)药物的研发,已成为肿瘤治疗领域的热点。此类新型靶向药物的理论基础区别于传统上单纯的靶向联合化疗,是以单克隆抗体作为化疗的载体,将化疗药物精准释放到肿瘤细胞内部,既能够实现1+1>2的抗肿瘤效应,又能体现高效低毒的治疗优势。全文结合对ADC药物发展历程的论述,展望HER2阳性乳腺癌靶向治疗未来的前进方向。The development of antibody-drug conjugates(ADC)has become a hot spot in the field of cancer therapy.The theoretical basis of this new type of targeted drugs that is different from the traditional ones combined chemotherapy,uses monoclonal antibodies as the carrier of chemotherapy to accurately release chemotherapy drugs into the tumor cells,which can not only achieve the anti-tumor effect more than expected,but also reflect the therapeutic advantages of high efficiency and low toxicity.This article reviews the development history of ADC drugs development and points out the future direction of targeted therapy for HER2-positive breast cancer.

关 键 词：抗体药物偶联物 乳腺癌 HER2 靶向治疗 精准医学 

分 类 号：R737.9[医药卫生—肿瘤]